Polymorphic oxidation of debrisoquine in bladder cancer.
The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96.6% of patients and 93.9% of controls with a metabolic ratio of debrisoquine less than 12.6 were classified as extensive metabolizers of debrisoquine (P = NS). The distribution of frequencies of metabolic ratio values tended to have lower values in the patients (P less than 0.05), reflecting a higher oxidative rate of debrisoquine in urothelioma patients that cannot be explained solely in terms of enzymatic induction by drugs, tobacco or alcohol. Patients with a high occupational risk for urothelioma had lower metabolic ratio values (P = 0.03). Our results suggest that oxidative polymorphism of debrisoquine might be related to the pathogenesis of bladder cancer.
Benítez
J
J
Department of Pharmacology, University of Extremadura, Badajoz, Spain.
Ladero
J M
JM
Fernández-Gundín
M J
MJ
Llerena
A
A
Cobaleda
J
J
Martínez
C
C
Muñoz
J J
JJ
Vargas
E
E
Prados
J
J
González-Rozas
F
F
D000368:Aged; D000428:Alcohol Drinking; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000378:metabolism*; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000378:metabolism*; D008297:Male; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic; D012307:Risk Factors; D012907:Smoking; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism*
D007546:Isoquinolines; D003647:Debrisoquin